Title
A novel imaging based Nomogram for predicting post-surgical biochemical recurrence and adverse pathology of prostate cancer from pre-operative bi-parametric MRI.

Permalink
https://escholarship.org/uc/item/1n39k7w8

Authors
Li, Lin
Shiradkar, Rakesh
Leo, Patrick
et al.

Publication Date
2021

DOI
10.1016/j.ebiom.2020.103163

Peer reviewed
Research paper

A novel imaging based Nomogram for predicting post-surgical biochemical recurrence and adverse pathology of prostate cancer from pre-operative bi-parametric MRI

Lin Li, Rakesh Shiradkar, Patrick Leo, Ahmad Alghorya, Pingfu Fu, Sree Harsha Tirumani, Amr Mahran, Christina Buzzy, Verena C Obmann, Bahar Mansoori, Ayah El-Fahamawi, Mohammed Shahai, Ashutosh Tewari, Cristina Magi-Galluzzi, David Lee, Priti Lai, Lee Ponsky, Eric Klein, Andrei S. Purysko, Anant Madabhushi

Center for Computational Imaging and Personalized Diagnostics, Case Western Reserve University, Cleveland, OH, USA
Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, USA
Department of Radiology, University Hospitals, Cleveland, OH, USA
Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA
Department of Radiology, Case Western Reserve University and University Hospitals Cleveland Medical Centers, Cleveland, OH, USA
Department of Diagnostic, Interventional and Pediatric Radiology (DIPR), Inselspital, Bern University Hospital, University of Bern, Switzerland
Department of Radiology, Abdominal Imaging Division, University of Washington, Seattle, WA, USA
Penn Medicine, University of Pennsylvania Health System, PA, USA
Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
Department of Pathology, University of Alabama at Birmingham, AL, USA
Case Western Reserve University School of Medicine, Cleveland, OH, USA
Gluckman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA
Imaging Institute, Cleveland Clinic, Cleveland, OH, USA
Louis Stokes Cleveland Veterans Administration Medical Center, USA

ARTICLE INFO

Article History:
Received 3 September 2020
Revised 20 November 2020
Accepted 23 November 2020
Available online xxx

Keywords:
Prostate cancer
Biochemical recurrence
Adverse pathology
Radiomic
MRI
Prognosis

ABSTRACT

Background: We developed and validated an integrated radiomic-clinicopathologic nomogram (RadClip) for post-surgical biochemical recurrence free survival (bRFS) and adverse pathology (AP) prediction in men with prostate cancer (PCa). RadClip was further compared against extant prognostics tools like CAPRA and Decipher.

Methods: A retrospective study of 198 patients with PCa from four institutions who underwent pre-operative 3 Tesla MRI followed by radical prostatectomy, between 2009 and 2017 with a median 35-month follow-up was performed. Radiomic features were extracted from prostate cancer regions on bi-parametric magnetic resonance imaging (bpMRI). Cox Proportional-Hazards (CPH) model warped with minimum redundancy maximum relevance (MRMR) feature selection was employed to select bpMRI radiomic features for bRFS prediction in the training set (D1, N = 71). In addition, a bpMRI radiomic risk score (RadS) and associated nomogram, RadClip, were constructed in D1 and then compared against the Decipher, pre-operative (CAPRA), and post-operative (CAPRA-S) nomograms for bRFS prediction in the training set (D1, N = 127).

Findings: "RadClip yielded a higher C-index (0.77, 95% CI 0.65-0.88) compared to CAPRA (0.68, 95% CI 0.57-0.8) and Decipher (0.51, 95% CI 0.33-0.69) and was found to be comparable to CAPRA-S (0.75, 95% CI 0.65-0.85). RadClip resulted in a higher AUC (0.71, 95% CI 0.62-0.81) for predicting AP compared to Decipher (0.66, 95% CI 0.56-0.77) and CAPRA (0.69, 95% CI 0.59-0.79)."

Interpretation: RadClip was more prognostic of bRFS and AP compared to Decipher and CAPRA. It could help pre-operatively identify PCa patients at low risk of biochemical recurrence and AP and who therefore might defer additional therapy.

Funding: The National Institutes of Health, the U.S. Department of Veterans Affairs, and the Department of Defense.

© 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

* Corresponding author at: Center for Computational Imaging and Personalized Diagnostics, 2071 Martin Luther King Drive, Cleveland, Ohio 44106-7207, Wickenden 523.

E-mail address: axm788@case.edu (A. Madabhushi).

https://doi.org/10.1016/j.ebiom.2020.103163
2352-3964/© 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
**Research in Context**

**Evidence before this study**

Prostate cancer (PCa) is the most common cancer among men. Approximately 20 to 40 percent of patients experience biochemical recurrence (BCR) following definitive therapy, and may further develop metastasis. Several tools, such as the Prostate Cancer Risk Assessment (CAPRA) score, Post-surgery Prostate Cancer Risk Assessment (CAPRA-S) score, and Decipher genomic test, have been proposed to identify patients who are at risk of developing BCR or adverse pathology (AP). AP is known to be strongly associated with risk of BCR and metastasis. Recently, radiomic features derived from bi-parametric magnetic resonance imaging (bpMRI) have been shown to capture sub-visual texture patterns for quantitative characterization of tumors phenotypes, and radiomic classifiers have been shown to aid in PCa risk stratification. Integrating pre-operative bpMRI derived radiomic parameters with clinicopathologic parameters may allow for even better prognostication of AP and PCa-specific outcome.

**Added value of this study**

In this study, we developed a prognostic nomogram, RadClip, and incorporated radiomic features extracted from bpMRI with pre-operative clinicopathologic parameters. Following an independent, multistate validation, we found that pre-operative RadClip was more prognostic of BCR and AP compared to Decipher and CAPRA for PCa patients who had undergone radical prostatectomy.

**Implications of all the available evidence**

The radiomic nomogram presented in this study could be potentially used as a surrogate to genomic-based prognostic tests to identify PCa patients with low risk of BCR and AP and who therefore might defer additional therapy.

**Introduction**

Radical prostatectomy (RP) is one of the primary treatments for localized prostate cancer (PCa) [1]. However, approximately 20% to 40% of patients experience biochemical recurrence (BCR) who may further develop metastasis after definitive treatment [2–4]. In addition, it has been shown that 25% of patients with low PCa volume and biopsy Gleason Grade Group (GG) 2 harbor adverse pathology (AP) [5], which is known to be a predictor for developing BCR and subsequent metastasis [6,7], and thus indicates exclusion of active surveillance [8].

Several tools have been proposed to identify patients at risk of presence of AP at final pathology [8], developing BCR [9,10], and subsequent metastasis [9–11]. These have included pre-operative tools, such as Prostate Cancer Risk Assessment (CAPRA) score, which was used to predict AP, risk of BCR and metastasis, and prostate cancer—specific survival [10]; and post-operative tools like Post-surgery Prostate Cancer Risk Assessment (CAPRA-S) score, which was developed to predict risk of BCR and metastasis after RP [9]. These assessments integrate factors, such as prostate—specific antigen (PSA); GG, surgical margin (SM) status, extracapsular extension (EPE), seminal vesicle invasion (SVI), and lymph node involvement (LNI), which have been previously shown to be significantly associated with risk of BCR [9]. However, these tools based on clinicopathological features failed to account for tumor molecular heterogeneity and their performance varies between different cohorts. In the last decade, there has been heightened interest in exploring the utility of different genomic signatures in predicting oncological outcomes after RP; the most utilized test in the real world practice is Decipher which has been shown to correlate with increased cumulative incidence of BCR, metastasis and PCa-specific mortality [12].

Pre-operative multi-parametric magnetic resonance imaging (mpMRI) has been utilized to help in PCa diagnosis [13], planning for surgery [14] and to predict the presence of AP, e.g. SVI [15] and EPE [16]. Recently, mpMRI radiomic derived features have shown to capture of sub-visual texture patterns for quantitative characterization of tumors phenotypes, and help in PCa risk stratification [17–20]. Integrating pre-operative mpMRI derived radiomic parameters with clinicopathologic parameters may allow for even better prognostication of AP and PCa specific outcome.

In this study, we sought to develop and evaluate a radiomic risk score (RadS) derived from bi-parametric MRI (bpMRI), including T2-weighted (T2WI) and Diffusion Weighted Imaging (DWI), for prediction of biochemical recurrence free survival (bRFS) and AP. Additionally, we also constructed a novel nomogram, RadClip, by integrating RadS, pre-operative prostate-specific antigen (PSA) and biopsy GG. RadClip was compared against the Decipher test, and the pre-operative CAPRA and post-operative CAPRA-S nomograms for bRFS and AP prediction on a multi-site validation set.

**Materials and methods**

**Ethics statement**

This retrospective study was approved by the Case Western Reserve University Institutional Review Board reviews (IRB) and was compliant with the Health Insurance Portability and Accountability Act (HIPAA); de-identified data were used, and no protected health information was needed. The need for an informed consent from all patients was waived by the IRB.

**Patient selection**

A total of 408 PCa patients from four institutions who had undergone pre-operative 3 Tesla (3T) prostate mpMRI between 2009 and 2017 were initially identified. Patients who met the following criteria were selected: patients who had (1) undergone RP after the MRI; (2) no history of neoadjuvant or adjuvant therapy; (3) images of adequate quality; and (4) and follow up information which includes postoperative serum PSA measurements (Fig. 1). Patients were excluded if they (1) were without T2WI or Apparent Diffusion Coefficient (ADC) maps; (2) were of sub-optimal image quality, e.g. ADC map distortion; (3) received radiation therapy (RT) as the definitive treatment, due to the difference in definition of BCR between RP and RT [2–4]; (4) were with PSA persistence; or (5) received additional therapies before RP.

A total of 198 patients that met the above eligibility criteria with a median follow-up of 35 months were identified, of these 106 men also underwent the Decipher test on PCa tissue sampled from the corresponding surgical specimen. (Table 1) 71 patients from a single site comprised the training set (Dtr), the remaining patients comprised the independent test set (Dte, N=127).

BCR was defined as 2 consecutive serum PSA > 0.2 ng/mL; bRFS was defined as the interval between the date of RP and the date of BCR [21]. Patients who were still alive without BCR at the last reported follow-up or the date of additional therapy applied were labeled as censored. AP was defined as the presence of SVI, EPE or LNI on the surgical specimen.

**MRI Protocol and prostate cancer delineations**

All patients were imaged on 3T MRI scanners with either a surface pelvic phased-array coil (PPAC) or an endorectal coil (ERC). All studies
15 subjects obtained over a period of 2 weeks using the same scanner work (QIN) [31]. This dataset involved test-retest 3T mpMRI scans of excluded using test-retest scans from the Quantitative Imaging Network. Statistics including mean, standard deviation, skewness, and kurtosis were calculated for each voxel-wise radiomic feature to characterize its distribution within each PCa lesion region.

Intensity drift artifacts across different MRI acquisitions cause T2WI to lack in tissue-specific meaning. Therefore, a nonparametric intensity standardization method [23] was used to align T2WI intensity distributions. In addition, bias-field artifacts introduced by the endorectal coil were corrected using a previously published method in which the estimated bias field is subtracted from the acquired image data [24]. Both T2WI and ADC maps were resampled to the same spatial resolution in the axial plane (0.5 × 0.5 mm). After pre-processing, 200 radiomic feature, including first and second order statistics, Gabor [25], Laws [26], Haralick [27] and CoLlAGe features [28], were extracted on a per-voxel basis within PCa lesion regions on both T2WI and ADC maps. These features characterize the underlying texture, quantify heterogeneity on imaging, and have previously been shown to be promising in PCa characterization [17,29,30]. Statistics including mean, standard deviation, skewness, and kurtosis were calculated for each voxel-wise radiomic feature to characterize its distribution within each PCa lesion region.

Statistics

**Feature selection and stability assessment.** Highly correlated (Pearson’s correlation coefficient (R) > 0.9) radiomic features were first eliminated and unstable radiomic features were further excluded using test-retest scans from the Quantitative Imaging Network (QIN) [31]. This dataset involved test-retest 3T mpMRI scans of 15 subjects obtained over a period of 2 weeks using the same scanner with PCa lesions annotated separately on each scan [31]. The rationale behind using these QIN cases was that stable radiomic features should remain relatively consistent across the test-retest scans of the same patient. Consequently, we only included stable radiomic features which are identified as those without significant difference (p < 0.05, Wilcoxon signed-rank test) between the test-retest scans. Minimum Redundancy Maximum Relevance (mRMR) [32] feature selection with multivariable Cox-Proportional Hazards (CPH) model was employed to identify the set of radiomic features and corresponding CPH model that produced highest C-index for bRFS prediction on D1. The top 5 most frequently selected radiomic features across multiple iterations of 5-fold and 10-run cross-validation were employed to construct the radiomic model producing a radiomic risk score (RadS) to estimate bRFS. Moreover, a radiomic-clinico-pathologic nomogram (RadClip), integrating RadS and pre-operative PSA and biopsy GG, was constructed based on the multivariable CPH model for 3-year bRFS prediction. (Fig. 2) RadClip and RadS were both constructed using the rms packages in R software version 3.6.

**Validation.** RadS was then evaluated on D2. Both the univariable and multivariable CPH models were fitted with RadS and clinicopathologic parameters, including biopsy GG, Prostate Imaging-Reporting and Data System version 2 (PI-RADS v2) score [33], age, pre-operative PSA, and clinical stage (cT, T2 or T3), to evaluate the role of radiomic features in the prediction of bRFS after RP. A head-to-head comparison between RadClip, Decipher, CAPRA, and post-surgical CAPRA-S score was conducted on subgroups of patients in D2 for bRFS prediction, who either underwent Decipher test (N = 106) or had sufficient information to calculate the CAPRA (N = 106) or CAPRA-S (N = 121) scores, in terms of concordance index (C-index) and Kaplan-Meier curves. Both Decipher risk score, ranging 0-1, and Decipher risk groups (low risk group with Decipher risk score < 0.4, intermediate 0.4-0.6, high > 0.6) [12] were included for comparison. Hazard ratios (HRs) of the multivariable CPH model indicate the influence of corresponding predictors. Wald test was applied and P values under .05 were considered to be statistically significant. Decision curve analysis was adopted to calculate the net benefit for RadClip, CAPRA score and CAPRA-S score in comparison to default strategies of treating all or no patients [34]. Area under receiver operating characteristic curve (AUC) was used to evaluate association between AP and pre-

![Flowchart of patient selection from four institutions. RT = radiation therapy; RP = radical prostatectomy; BCR = biochemical recurrence; mpMRI = multi-parametric magnetic resonance imaging.](image)
operative prognostic models RadClip, CAPRA, and Decipher on $D_2$. We also evaluated the association between RadClip and the presence of SVI, EPE or LNI separately, and then compared RadClip with CAPRA, CAPRA-S, and Decipher in terms of AUC.

**Role of the funding source**

The sponsors of this study had no role in the research design, data collection, data analysis, data interpretation, and paper writing. The

---

### Table 1

Demographic and disease characteristics of all 198 study patients.

| Dataset | $D_1$Training | $D_2$Validation |
|---------|---------------|-----------------|
| Cohort | CC | MS | UP | UH | DE |
| # patients | 71 | 31 | 20 | 20 | 56 |
| Median age, (range) | 59 (47-79) | 63 (48-73) | 64 (49-73) | 61 (47-86) | 64 (42-76) |
| Mean pretreatment PSA ± SD, ng/mL (range) | 10.0 ± 5.0 (3.7 - 22.5) | 8.8 ± 1.6 (1.2 - 8.9) | 10.6 ± 18.5 (1.8 - 88.3) | 9.0 ± 12.1 (1.2-69.4) |
| Biopsy GG, n/# patients (%) | 1 | 0/20 (0) | 0/20 (0) | 20/20 (100) | 20/20 (100) |
| Pathologic GG, n/# patients (%) | 1 | 0/31 (0) | 0/20 (0) | 0/20 (0) | 0/31 (0) |
| PI-RADS v2, n/# lesions (%) | 1 | 0/71 (0) | 0/31 (0) | 0/20 (0) | 0/20 (0) |
| Decipher risk categories, n/# patients (%) | 1 | 6/31 (19.35) | 18/20 (90) | 8/20 (40) | 16/67 (23.88) |
| CAPRA, n/# patients (%) | 1 | 24/71 (33.80) | 4/31 (12.90) | 2/20 (10) | 4/20 (20) |
| CAPRA-S, n/# patients (%) | 1 | 12/71 (16.90) | 0/31 (0) | 0/20 (0) | 0/20 (0) |
| BCR n/# patients (%) | 1 | 33/71 (46.48) | 21/31 (67.74) | 10/20 (50) | 8/20 (40) |
| SVI, n/# patients (%) | 1 | 2/71 (2.82) | 2/31 (6.45) | 1/20 (5) | 2/20 (10) |
| EPE, n/# patients (%) | 1 | 30/71 (42.25) | 21/31 (67.74) | 10/20 (50) | 12/20 (60) |
| LNI, n/# patients (%) | 1 | 18/71 (25.35) | 0/31 (0) | 0/20 (0) | 0/20 (0) |
| PSM, n/# patients (%) | 1 | 15/31 (48.39) | 18/20 (90) | 8/20 (40) | 18/20 (90) |
| CT, n/# patients (%) | 1 | 0/1 (0) | 0/20 (0) | 0/20 (0) | 0/20 (0) |

PSA = prostate-specific antigen, GG = Grade Group, PI-RADS v2 = Prostate Imaging Reporting and Data System version 2, BCR = Biochemical Recurrence, SVI = Seminal Vesicle Invasion, EPE = Extra Prostatic Extension, LNI = Lymph Node Invasion, PSM = Positive Surgical Margin, CT = clinical stage, NA = Not Available.
Table 2
MRI scan parameters.

| Parameter                  | Institution 1 | Institution 2 | Institution 3 | Institution 4 |
|----------------------------|---------------|---------------|---------------|---------------|
|                             | Scanner 1     | Scanner 2     | Scanner 1     | Scanner 1     |
| **Manufacturer**            | Philips Medical Systems, Best, Netherlands | Siemens Healthcare, Erlangen, Germany | Siemens Healthcare, Erlangen, Germany | Siemens Healthcare, Erlangen, Germany |
| **Model**                   | 3T Achieva    | 3T Skyra      | 3T Skyra      | 3T Skyra      |
| **Coils**                   | ERC           | PPAC          | PPAC          | ERC           |
| **T2WI**                    |               |               |               |               |
| TR/TE                      | 3802–5151/105–115 | 3730/121 | 5610/121 | 3000-6000/80-120 |
| Acquisition time (min)     | 5.36          | 2.53          | 2.54          | 2.25          |
| Reconstruction voxel size (mm³) | 0.3 × 0.3 × 3.0 | 0.5 × 0.5 × 3.0 | 0.3 × 0.3 × 3.0 | 0.3 × 0.3 × 3.0 |
| **DWI**                     |               |               |               |               |
| TR/TE                      | 3571–4880/50–74 | 4700/86 | 8700/72 | 7900/88 |
| Acquisition time (min)     | 5.25          | 5.07          | 2.57          | 2.34          |
| Reconstruction voxel size (mm³) | 1.4 × 1.4 × 3.0 | 1.6 × 1.6 × 3.0 | 2.2 × 2.2 × 3 | 1.4 × 1.4 × 3.0 |
| b-values (s/mm²)           | 0.0, 500, 1000, 1500, 2000 | 0.400, 900, 1500 | 50,1000,1600,2000 | 0, 1000, 1400 |
| Acquisition time (min)     |               |               | 2.57          | 3-6            |
| b-values (s/mm²)           |               |               | 2.57          | 3-6            |
| Acquisition time (min)     |               |               | 2.57          | 3-6            |

TR = repetition time, TE = echo time, T2WI = T2-weighted imaging, DWI = diffusion-weighted imaging, PPAC = pelvic phased-array coil, ERC = endorectal coil.

Fig. 2. Overall workflow and pipeline. T2WI = T2-weighted magnetic resonance imaging; ADC = apparent diffusion coefficient.
corresponding authors had full access to all data obtained from this study and had final responsibility for the decision to submit for publication.

**Results**

**Ability of radiomic model to predict bRFS**

RadS was built with 5 radiomic features selected within $D_1$. (Table 3 and Fig. 3) RadS on $D_2$ resulted in an HR = 7.01 (95% CI, 1.21 – 40.68, $p < .05$) on multivariable analysis. RadS was significantly associated with bRFS and found to be prognostic independent of other pre-operative clinicopathologic parameters, including biopsy GG, PI-RADS v2, age, pre-operative PSA, and cT, to predict bRFS. (Table 4).

**Ability of RadClip to predict bRFS and head-to-head comparisons**

The prognostic performance of RadClip was validated on $D_2$, resulting in a HR of 1.9 (95% CI, 1.4-2.7, $p < .05$) and C-index of 0.77 (95% CI, 0.65-0.88). For the patients in $D_2$, neither the Decipher risk score (C-index 0.51, 95% CI 0.33-0.69, N=106) nor associated risk groups (C-index 0.5, 95% CI 0.35-0.65, N=106) showed any significant association with bRFS in univariable analysis. (Table 5) RadClip achieved a higher C-index than CAPRA (0.77 vs. 0.68, N=106) and a similar C-index to CAPRA-S (0.77 vs. 0.75, N=121). (Table 3) In addition, RadClip illustrated significant association with bRFS independent of CAPRA, CAPRA-S and Decipher in the multivariable analysis. (Table 5) Furthermore, RadClip yielded a similar net benefit compared to CAPRA and CAPRA-S across decision threshold probabilities ranging from 20-30% [2,3,21] (Fig. 4).

### Table 3

| Biochemical-recurrence-associated Radiomic features | Radiomic feature description |
|--------------------------------------------------|-----------------------------|
| T2WI Laws feature Wave texture distribution kurtosis |
| T2WI Laws feature Wave-ripple texture distribution kurtosis |
| T2WI intensity range Local intensity range distribution kurtosis |
| T2WI Haralick Information measure Intensity heterogeneity distribution kurtosis |
| ADC Laws feature Wave and edge texture distribution kurtosis |

T2WI = T2-weighted imaging, ADC = apparent diffusion coefficient.

**Fig. 3.** BCR-associated Radiomic features. (a) and (c) are the bpMRI of a 59-year-old patient with BCR identified at 41-month follow-up. The patients had pathologic Gleason Grade Group = 2, PI-RADS v2 = 2, Decipher risk score = 0.52, CAPRA score = 3, CAPRA-S score = 2, no adverse pathology identified. (b) and (d) are the bpMRI of a 62-year-old patient with no BCR identified at 45-month follow-up. The patient had pathologic Gleason Grade Group = 2, PI-RADS v2 = 4, Decipher risk score = 0.63, CAPRA score = 3, CAPRA-S score = 4, no adverse pathology identified. (a,b) T2WI Haralick information measures; (c,d) ADC Laws feature capturing wave-edge pattern. BCR = biochemical recurrence; bpMRI = bi-parametric magnetic resonance imaging; PI-RADS v2 = Prostate Imaging-Reporting and Data System version 2; CAPRA = Prostate Cancer Risk Assessment; CAPRA-S = Post-surgery Prostate Cancer Risk Assessment; T2WI = T2-weighted magnetic resonance imaging; ADC = apparent diffusion coefficient.
Table 4
Multivariable Biochemical-Recurrence-Free Survival analysis (N = 127, 22 BCR +)

| Parameter name | Multivariable HR (95% CI) | Multivariable C-index (95% CI) | Multivariable p-value |
|----------------|----------------------------|-------------------------------|-----------------------|
| Biopsy GG      | 1.67 (1.09-2.57)           | 0.79 (0.69-0.88)              | 0.02*                 |
| PI-RADS        | 0.99 (0.53-1.84)           |                               | 0.97                  |
| PSA            | 1.04 (1.00-1.08)           |                               | 0.071                 |
| Age            | 0.92 (0.85 – 0.98)         |                               | 0.013*                |
| Clinical Stage | 1.92 (0.91 – 4.04)         |                               | 0.087                 |
| RadS           | 7.01 (1.21 – 40.68)        |                               | 0.03*                 |

Table 5
Head to head comparison between RadClip, CAPRA and Decipher in BCR prediction.

| Model                  | HR (95% CI) | C-index (95% CI) | Univariable p-value | Multivariable p-value |
|------------------------|-------------|-----------------|---------------------|-----------------------|
| RadClip, RadS and CAPRA (N = 106, 18 BCR+) | 1.9 (1.4-2.7) | 0.77 (0.65-0.88) | <0.001* | 0.012* |
| CAPRA                  | 1.4 (1.1-1.9) | 0.68 (0.57-0.8)  | 0.007*              | 0.336                |
| RadClip, RadS, and CAPRA-S (N = 121, 21 BCR+) | 2 (1.5-2.4) | 0.77 (0.66-0.87) | <0.001* | 0.011* |
| CAPRA-S                | 1.4 (1.2-1.6) | 0.75 (0.65-0.85) | <0.001* | 0.046* |
| RadClip and Decipher (N = 106, 14 BCR+) | 1.6 (1.1-2.4) | 0.73 (0.59-0.87) | 0.033* | 0.041* |
| Decipher score         | 2.5 (0.17-37) | 0.51 (0.33-0.69) | 0.51                | 0.73                |
| Decipher risk group    | 1.1 (0.61-2) | 0.5 (0.35-0.65)  | 0.74                | 0.77                |

Association between pre-operative prognostic models and AP

We evaluated the association between RadClip and AP among patients from the validation set with EPE, SVI, and LNI specific information. RadClip yielded an AUC = 0.71 (95% CI, 0.62-0.81, p < .05) in predicting AP, compared to CAPRA, AUC = 0.69 (95% CI, 0.59-0.79, p < .05), and Decipher, AUC = 0.66 (95% CI, 0.57-0.77, p < .05), on Do2. In addition, RadClip had a higher AUC compared with CAPRA and Decipher in predicting EPE, SVI and LNI (Table 6).

Discussion

The ability to predict prognosis of prostate cancer (PCa) patients using pre-operative imaging and clinicopathologic parameters may allow for identification of patients who are more likely to have adverse pathologic factors, such as extracapsular extension (EPE), seminal vesicle invasion (SVI), and lymph node involvement (LNI). This could allow for identifying men who are not candidates for active surveillance (AS), but rather candidates for more aggressive treatments. Additionally, since the benefit of adjuvant radiation therapy is subject to debate [36], pre-operatively identifying patients with low risk of developing BCR after surgery could give clinicians more confidence in deferring additional treatments in these men. In this study, we developed a novel radiomic risk score, RadS, derived from computerized texture features from pre-surgical bi-parametric MRI that was shown to be independently prognostic of biochemical recurrence free survival (bRFS). Additionally, we presented RadClip, a pre-operative nomogram that combines radiomic features with clinicopathologic parameters (including biopsy Gleason Grade Group and pre-surgical PSA) to predict bRFS, as well as AP.

Results from our study indicate that Haralick features extracted from pre-operative T2WI and Laws features derived from both T2WI and ADC map showed significant differences between patients with and without BCR. Haralick features [27] capture spatial intensity based heterogeneity and Laws [26] features capture edge and wave texture patterns on MRI. Haralick features of PCa on T2WI have been previously shown to be associated with biochemical recurrence (BCR) [17,29], men who had BCR following surgery tended to have a higher expression of Haralick features within the tumor on pre-operative T2WI versus those who did not. Additionally, Laws features derived from prostate bpMRI lesion regions have also been shown to be associated with PCa aggressiveness, in particular with RP Gleason grade [30]. We observed that patients with poor prognosis tended to have higher expression of T2WI Haralick feature and edge and wave texture within tumor regions on ADC maps, suggesting a higher degree of morphologic disease specific heterogeneity. (Fig. 3 and Table 3)

In our study, the performance of both CAPRA and CAPRA-S for the task of bRFS prediction was found to be consistent to results reported in previous studies [10]. RadClip, as a pre-operative prognostic nomogram was found to outperform CAPRA score and achieve similar performance as the post-surgical CAPRA-S score in a head-to-head comparison for bRFS prediction. These results illustrated the potential of RadClip to predict prognosis pre-operatively which will allow for identification of patients who could potentially benefit from receiving neo-adjuvant therapy. In addition, RadClip also showed strong association with AP, suggesting its possible utility in pre-operative identification of men with PCa who should likely be excluded from consideration for active surveillance.

While the Decipher test has been previously validated in its ability to predict risk of metastasis and PCa specific mortality [12,36], in our study the test did not show a significant association with bRFS. This may have been because the Decipher test was initially validated to predict risk of metastasis and not BCR per se [11]. Interestingly, a previous study [36] also appeared to corroborate our findings, suggesting that the Decipher risk score did not have a strong association with post-surgical BCR. Decipher was shown to have significant association with AP in our validation cohort. However, note that in this study, Decipher was performed post-surgically on the resected specimens, unlike RadClip which was assessed pre-operatively. Although a previous study has suggested that Decipher estimated on biopsy tissue was similar to the corresponding score estimated on the surgical specimens [37], the biopsy sampling error may still be a concern indicating by another study as no correlation between Decipher score estimated from index lesions and benign regions [38]. Unlike Decipher, RadClip is also completely tissue non-destructive and is not constrained by the limitations of biopsy sampling errors. Also, since RadClip only requires diagnostic mpMRI, the test does not consume tissue like molecular tests like Decipher. We acknowledge the fact that post-surgery Decipher test is usually reserved for patients with T2 and positive surgical margins, T3a/b, PSA persistence, and in selected cases of BCR; therefore, the comparison between RadClip and Decipher may seem counter-intuitive but it reflects over-utilization of Decipher test in this population as 45/106 patients had low risk score.

The application of assessing the association between mpMRI derived parameters, e.g. PI-RADS v2 score or lesion volume, with BCR, PCa aggressiveness and molecular tests like Decipher is not new [39,40]. Jambor et. al. illustrated that combining clinicopathologic parameters with mpMRI was comparable in prediction of BCR as a combination of Decipher and clinicopathologic parameters [40]. This study was however limited in its sample size, single institutional design and the fact that PI-RADS is known to be subject to inter-reader variability [41]. Similarly, Shiradkar et. al. illustrated using bpMRI derived radiomic features could be prognostic of BCR [17]. However, this study too was limited to scans from a single site in their validation set. Our study differed from previous studies [17–20,29] in a few different ways. Firstly, instead of investigating the correlation between radiomic features and Decipher risk categories or pathologic Gleason Grade [18], we directly built a nomogram.
to predict clinical endpoints, e.g. BCR and AP. In addition, unlike previous approaches that have attempted to directly train radiomic classifiers against binary outcome (e.g., presence or absence of BCR) [17,29,40], our approach employed a Cox proportional hazards approach to build an imaging based prognostic model accounting for time to BCR as also censoring information introduced by the variance of follow-up time among patients. Moreover, this was also one of the very few studies we are aware of to validate an MRI based PCa prognostic tool in a multi-institutional setting [19,29,40]. The findings of RadClip on scans from 4 institutions, suggest that the approach is...
relatively robust and resilient to scanner and site-specific MRI varia-
tions.

We acknowledge however that our study did have its limitations.
First, implicit bias may exist due to the retrospective nature of the
study; however, the multi-institutional validation suggests the
robustness of RadClip. In addition, even though 198 patients were
included in this study, this number is actually larger compared to
other recent related studies [17,18,40]. However, we acknowledge
that prior to clinical deployment, the approach needs additional re-
trospective and potentially prospective clinical trial validation in
the future to further confirm the generalizability of our findings.
Second, this study employed BCR as a surrogate endpoint for metastasis
because of insufficient follow-up time after RP, as opposed to meta-
tasis. Furthermore, we demonstrated that the nomogram was prog-
nostic and not predictive of added benefit of neoadjuvant or adjuvant
therapy, though that it will certainly be included for our future work.
Also, an automated lesion detection and segmentation module on the
MRI scans could be implemented in consort with RadS and RadClip in
future.

In spite of these limitations, our study suggests that with addi-
tional independent multi-site validation, these radiomic features
could potentially be used for pre-operative risk stratification in
patients with PCa to allow for more effective treatment management.

Conclusion

In this study, we developed a prognostic nomogram, RadClip,
integrating radiomic features derived from pre-operative bio-
parametric MRI, biopsy GC and pre-operative PSA to predict bio-
chemical recurrence free survival and adverse pathology in prostate
cancer patients undergoing prostatectomy. RadClip outperformed
Decipher risk score and CAPRA score on a limited hold-out validation
set.

Declaration of Competing Interests

Dr. Madabhushi is an equity holder in Elucid Bioimaging and in
Inspirata Inc. In addition, he has served as a scientific advisory board
member for Inspirata Inc, AstraZeneca, Bristol Meyers-Squibb and
Merck. Currently he serves on the advisory board of Aiforia Inc.
He also has sponsored research agreements with Philips, AstraZeneca
and Bristol Meyers-Squibb. He has 15 relevant issued patents (USSN:
10,550,570; USN: 10,607,112; USN: 10,004,471 USN: 10,254,358,
USN: 10,398,399; USN: 10,650,515; USN: 8,774,479; USN: 8,295,575,
USN: 8,442,285; USN: 9,159,128, USN: 9,177,104 B2, USN: 9,235,887
USN: 9,262,583, USN: 9,483,822, USN: 9,767,555) and 1 pending patent (CWRU1P139US). His technology has been
licensed (USSN: 8,442,285; USN: 8,442,285) to Elucid Bioimaging.
He is also involved in a NIH U24 grant with PathCore Inc, and 3
different R01 grants with Inspirata Inc.

Data sharing

The radiomic features generated during the current study with
analysis code are available in https://github.com/lynli/RadClip.

Acknowledgements

Research reported in this publication was supported by the National
Cancer Institute under award numbers 1U24CA199374-
01, R01CA202752-01A1, R01CA208236-01A1, R01CA216579-
01A1, R01CA220581-01A1, U01CA239055-01, U01CA248226-01,
1U54CA254566-01; National Heart, Lung and Blood Institute
1R01HL15127701A1, National Institute for Biomedical Imaging
and Bioengineering 1R43EB028736-01; National Center for
Research Resources under award number 1C06 RR12463-01; VA
Merit Review Award IBX004121A from the United States Depart-
ment of Veterans Affairs Biomedical Laboratory Research and Devel-
opment Servicethe Office of the Assistant Secretary of Defense
for Health Affairs, through the Breast Cancer Research Program
(W81XWH-19-1-0668), the Prostate Cancer Research Program
(W81XWH-15-1-0558, W81XWH-20-1-0851) the Lung Cancer
Research Program (W81XWH-18-1-0440, W81XWH-20-1-0595), the
Peer Reviewed Cancer Research Program (W81XWH-18-1-0404), the
Kidney Precision Medicine Project (KPMP) Glue Granthe Ohio Third
Frontier Technology Validation Fundthe Clinical and Translational
Science Collaborative of Cleveland (UL1TR0002548) from the
National Center for Advancing Translational Sciences (NCATS) com-
ponent of the National Institutes of Health and NIH roadmap for
Medical Research. The Wallace H. Coulter Foundation Program in
the Department of Biomedical Engineering at Case Western Reserve
University. The DOD Prostate Cancer Idea Development Award:
W81XWH-18-1-0524. Verena C Obmann received funding from the
Swiss National Science Foundation, Early Postdoc Mobility fellowship
grant, PZSPK3_178132.

The content is solely the responsibility of the authors and does
nenecessarily represent the official views of the National Institutes
of Health, the U.S. Department of Veterans Affairs, the Department
of Defense, or the United States Government.

References

[1] Tourinho-Barbosa R, Srougi V, Nunes-Silva I, Baghdadi M, Rembeyo G, Eiffel SS,
et al. Biochemical recurrence after radical prostatectomy: what does it mean? Int
J Urol Off J Braz Urol 2018;44(1):14–21.
[2] Freedland SJ, Humphreyes EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC,
et al. Risk of prostate cancer–specific mortality following biochemical recurrence
after radical prostatectomy. JAMA 2005 Jul 27;294(4):433–9.
[3] Williams S. Surrogate endpoints in early prostate cancer research. Trans Androl
Urol 2018 Jun;7(3):472–82.
[4] Van den Broeck T, van den Bergh RCN, Arfit N, Gross T, Moris L, Briet E, et al. Prog-
nostic value of biochemical recurrence following treatment with curative intent
for prostate cancer: a systematic review. Eur Urol 2019 Jun 1;75(6):967–87.
[5] Patel HD, Tosoian JJ, Carter HB, Epstein JI. Adverse pathologic findings for men
electing immediate radical prostatectomy: defining a favorable intermediate-risk
group. JAMA Oncol 2018 Jan 1;4(1):89–92.
[6] Bloom KD, Richie JP, Schulz, D, Renshaw A, Saegert D, D’Amico AV. Invasion
of seminal vesicles by adenocarcinoma of the prostate: PSA outcome determined
by preoperative and postoperative factors. Urology 2004 Feb 1;63(2):333–6.
[7] Mikel Hubanks J, Boorjian SA, Frank I, Gettman MT, Houston Thompson R, Rangel
LJ, et al. The presence of extracapsular extension is associated with an increased
risk of death from prostate cancer after radical prostatectomy for patients with
seminal vesicle invasion and negative lymph nodes. Urol Oncol Semin Orig Inves-
tig 2014 Jan 1;32(1):26.e1–7.
[8] Kim HL, Li P, Huang H-C, Dehesi S, Marti T, Knudsen B, et al. Validation of the
Decipher Test for predicting adverse pathology in candidates for prostate cancer
active surveillance. Prostate Cancer Prosttic Dis 2019 Sep;22(3):395–405.
[9] Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score. Cancer. 117(22):
5039–46.
[10] Bratbjord JS, Leapman MS, Cooperberg MR. The CAPRA Score at 10 years:
contemporary perspectives and analysis of supporting studies. Eur Urol 2017 May
1;71(5):795–8.
[11] Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, et al Discovery
and validation of a prostate cancer genomic classifier that predicts early metastasis
following radical prostatectomy. PLOS ONE 2013 Jun 24;8(6):e66855.
[12] Ross AE, Johnson MH, Yousefi N, de Ruiter D, Dorey FJ, Walsh PC, et al. Deci-
pher based genomics augments post-prostatectomy risk strati-
ation in a natural his-
tory cohort of intermediate- and high-risk men. Eur Urol 2016 Jan 1;69(1):157–
65.
[13] Ahmed HJ, El-Shater Bosaly A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al.
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer
[PROMIS]: a paired validating confirmatory study. The Lancet 2017 Feb 25;389
(10071):315–22.
[14] Marencio J, Orzyck C, Collins T, Moore C, Emberton M. Role of MRI in planning
radical prostatectomy: what is the added value? World J Urol 2019 Jul 1;37(7):1289–
96.
[15] Hegde JV, Demanes JD, Veruttipong D, Raine J, Park SJ, Ramani SS, et al. Pretreat-
ment 3T multiparametric MRI staging predictions for biochemical failure in high-risk
prostate cancer treated with combination high-dose-rate brachytherapy and
departmental brachytherapy. Brachytherapy 2017 Nov 1;16(6):1106–12.
[16] Winness A, Vargas HA, Donahue TF, Zheng J, Moskwitz C, Eastham J, et al. Diag-
osis of extracapsular extension of prostate cancer on prostate mri: impact of sec-
tion-oriented readings by subspecialized genitourinary oncologic radiologists.
Am J Roentgenol 2015 Jun 23;205(1):W73–8.
Penzias G, Singanamalli A, Elliott R, Gollamudi J, Shih N, Feldman M, et al. Radiomic features from pretreatment bivolumetric MRI predict prostate cancer biochemical recurrence: Preliminary findings. J Magn Reson Imaging 2018;48(6):1626–36.

Hectors SJ, Cherry M, Yadav KK, Beksaç AT, Thulassadass H, Lewis S, Davicioni E, Wang P, Tewari AK, Taouli B. Radiomics features measured with multiparametric magnetic resonance imaging predict prostate cancer aggressiveness. The Journal of urology 2019 Sep;202(3):498–505.

Bourbonne V, Valières M, Lucia F, Doucet L, Visvikis D, Tissot V, Pradier O, Hatt M, Schick U. MRI-derived radiomics to guide post-operative management for high-risk prostate cancer. Frontiers in Oncology 2019;9:807.

Abdollahi H, Mofid B, Shiri I, Razazghdoust A, Saadipoor A, Mahdavi A, et al. Machine learning-based radiomic models to predict intensity-modulated radiation therapy response. Gleason score and stage in prostate cancer. Radiol Med (Torino) 2019 Jun;124(6):555–67.

Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999 May 5;281(17):1591–7.

Pieper S, Halle M, Kikinis R, 3D Slicer. In: Proceedings of the 2nd IEEE international symposium on biomedical imaging: nano to macro (IEEE Cat No 04EX821), 1, 2004. p. 632–5.

Sled JC, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging 1998 Feb;17(1):87–97.

Juntu J, Sijbers J, Van Dyck D, Gielen J. Bias Field Correction for MRI Images. In: Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging 1998 Feb;17(1):87–97.

Fedorov A, Schwier M, Clunie D, Herz C, Pieper S, Kikinis R, et al. An annotated test-retest collection of prostate multiparametric MRI. Sci Data 2018 Dec 4;5:180281.

Peng Hanchuan, Long Fuhui, Ding C. Feature selection based on mutual information criteria of max-dependency, max-relevance, and min-redundancy. IEEE Trans Pattern Anal Mach Intell 2005 Aug;27(8):1226–38.

Weinreb JC, Barentsz JO, Choyke PL, Conard F, Haider MA, Macura KJ, et al. PI-rads prostate imaging – reporting and data system: 2015, version 2. Eur Urol 2016 Jan 1;69(1):16–40.

Vickers AJ, van Calster B, Steyerberg EW. A simple, step-by-step guide to interpreting decision curve analysis. Diagn Progn Res 2019 Oct 4;3(1):18.

Cooperberg MR, Davicioni E, Crisan A, Jenkins RB, Ghadessi M, Karnes RJ. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol 2015 Feb 1;67(2):326–33.

Klein EA, Haddad Z, Yousefi K, Lam LLC, Wang Q, Cheourng V, et al. Decipher genomic classifier measured on prostate biopsy predicts metastasis risk. Urology 2016 Apr 1;90:148–52.

Radtke JP, Takhar M, Bonekamp D, Kesch C, Erho N, du Plessis M, et al. transcriptome-wide analysis of magnetic resonance imaging-targeted biopsy and matching surgical specimens from high-risk prostate cancer patients treated with radical prostatectomy: the target must be hit. Eur Urol Focus 2018 Jul 1;4(4):540–6.

Purysko AS, Magi-Galluzzi C, Mian OY, Sittenfeld S, Davicioni E, Du Plessis M, Buerki C, Buell J, Li L, Madabhushi A, Stephenson A. Correlation between MRI phenotypes and a genomic classifier of prostate cancer: preliminary findings. European radiology 2019 Sep;29(9):4861–70.

Jambor L, Falagarìo U, Ratnani P, Perez IM, Demir K, Merisaari H, et al. Prediction of biochemical recurrence in prostate cancer patients who underwent prostatectomy using routine clinical prostate multiparametric MRI and decipher genomic score. J Magn Reson Imaging 2020;51(4):1075–85.

Girometti R, Giannarini G, Greco F, Isola M, Cereser L, Como C, et al. Interreader agreement of PI-RADS v. 2 in assessing prostate cancer with multiparametric MRI: A study using whole-mount histology as the standard of reference. J Magn Reson Imaging 2019;49(2):546–55.